Oral Semaglutide's Real-World Effectiveness on Glycemic Control and Weight Explored in Spanish Type 2 Diabetes Patients
Background
Type 2 Diabetes (T2D) remains a significant global health challenge, often requiring complex, lifelong management to prevent severe microvascular and macrovascular complications. While injectable glucagon-like peptide-1 receptor (GLP-1R) agonists have revolutionized T2D treatment by improving glycemic control and promoting weight loss, their injectable nature can be a barrier to adherence for some patients. Oral semaglutide (Rybelsus®) offers a non-injectable alternative, but its real-world performance, particularly concerning patient satisfaction and adherence in diverse clinical settings, warrants further investigation beyond controlled clinical trials. This study aims to bridge that gap by observing its use in routine Spanish clinical practice.
Study Design
This observational study is collecting real-world data on patients with Type 2 Diabetes in Spain who are prescribed oral semaglutide (Rybelsus®) as part of their routine clinical care. Participants will receive oral semaglutide as prescribed by their study doctor, with no specific dose or frequency mandated by the study protocol, reflecting actual clinical practice. The study duration is approximately 8-10 months. Primary endpoints include changes in blood sugar levels (e.g., HbA1c), body weight, and patient satisfaction with the treatment. Participants will complete a questionnaire during their regularly scheduled clinic visits to assess their adherence and satisfaction with Rybelsus® tablets.
Why It Matters
Understanding how oral semaglutide performs in a real-world setting, outside the strictures of randomized controlled trials, is crucial for optimizing Type 2 Diabetes management. This study's focus on patient satisfaction and adherence, alongside clinical outcomes like blood sugar and weight, provides valuable insights into the practical utility of an oral GLP-1R agonist. Real-world evidence can inform prescribing patterns, patient education strategies, and health policy decisions, particularly regarding the adoption of oral therapies. For individuals managing T2D, these findings could highlight the benefits of oral semaglutide in terms of convenience and sustained engagement with treatment, potentially improving long-term health outcomes and quality of life. The data will help clinicians better counsel patients on what to expect regarding efficacy and the practicalities of an oral regimen.
semaglutide
type 2 diabetes
observational study
real-world evidence
glp-1 agonist
spain